NexCAR19: A Landmark Step in India’s CAR-T Cell Revolution

Hematologic malignancies, such as leukemia and lymphoma, have demonstrated the effectiveness of CAR-T cell therapy, which is a recent innovation in cancer immunotherapy. Ongoing research is focused on the ability to treat solid tumors, autoimmune diseases, and cell platforms that have been genetically altered. There are issues such as tumor heterogeneity, immune evasion, and limited tumor infiltration that limit the effectiveness of therapies against solid tumors. CRISPR/Cas9- based genetic modifications and the targeting of multiple antigens are innovative solutions to these problems. There are also "armored" CAR-Ts that secrete cytokines to aid in therapy. Furthermore, promising, safer, and more scalable substitutes are provided by CAR-NK and CAR-Treg treatments. When taken as a whole, these developments portend a new generation of accurate, readily accessible, and adaptive cellular immunotherapies for a number of diseases.